marizomib

01/01/2016 - "Phase 1 study of marizomib in relapsed or relapsed and refractory multiple myeloma: NPI-0052-101 Part 1."
08/01/2022 - "Marizomib had advantages in the treatment of central nervous system-multiple myeloma (CNS-MM) because of its good central nervous system penetrability. "
01/01/2017 - "Marizomib for central nervous system-multiple myeloma."
01/01/2015 - "Marizomib has been termed as orphan drug against multiple myeloma by US Food and Drug Administration (FDA) in 2013 and by European Medicines Agency (EMA) in 2014. "
09/15/2016 - "Phase I Clinical Trial of Marizomib (NPI-0052) in Patients with Advanced Malignancies Including Multiple Myeloma: Study NPI-0052-102 Final Results."

01/01/2021 - "Due to the absence of curative treatments for glioblastoma (GBM), we assessed the efficacy of single and combination treatments with a translationally relevant 2nd generation TRAIL-receptor agonist (IZI1551) and the blood-brain barrier (BBB) permeant proteasome inhibitor marizomib in a panel of patient-derived glioblastoma cell lines. "
01/01/2021 - "This phase I/II trial in patients with recurrent glioblastoma (GBM) evaluates the safety and preliminary efficacy of marizomib, an irreversible pan-proteasome inhibitor that crosses the blood-brain barrier. "
01/01/2021 - "Marizomib alone or in combination with bevacizumab in patients with recurrent glioblastoma: Phase I/II clinical trial data."
01/25/2016 - "Induction of cell death by the novel proteasome inhibitor marizomib in glioblastoma in vitro and in vivo."

11/01/2005 - "In animal tumor model studies, NPI-0052 is well tolerated and prolongs survival, with significantly reduced tumor recurrence. "
01/01/2020 - "We demonstrate that marizomib-induced OXPHOS inhibition upregulates glycolysis to meet the energetic demands of TNBC cells and combined inhibition of glycolysis with marizomib leads to a synergistic anti-cancer activity. "
05/01/2008 - "The findings also suggest the therapeutic application of subtoxic NPI-0052 concentrations in combination with TRAIL/agonist DR4/DR5 mAbs in the treatment of TRAIL-resistant tumors."
05/01/2008 - "Treatment of PC-3 and Ramos cells with NPI-0052 (</=2.5 nM) and TRAIL sensitizes the tumor cells to TRAIL-induced apoptosis. "
09/15/2016 - "Phase I Clinical Trial of Marizomib (NPI-0052) in Patients with Advanced Malignancies Including Multiple Myeloma: Study NPI-0052-102 Final Results."

01/01/2021 - "Marizomib sensitizes primary glioma cells to apoptosis induced by a latest-generation TRAIL receptor agonist."
01/01/2017 - "Marizomib demonstrated encouraging activity in RRMM and has emerging clinical activity in glioma, making it a potential CNS-MM therapeutic intervention. "
01/01/2016 - "Encouragingly, the immunocompromised mice, intracranially implanted with glioma xenografts, survived significantly longer than the control animals (P < .05) when treated with marizomib. "
01/01/2016 - "The in-vitro antitumor activity of marizomib was studied in glioma cell lines U-251 and D-54. "
01/01/2016 - "Marizomib activity as a single agent in malignant gliomas: ability to cross the blood-brain barrier."

07/01/2007 - "These effects of NPI-0052, alone and in combination with HDACi, warrant further testing to determine the compound's clinical efficacy in leukemia."
07/01/2007 - "NPI-0052 also induces DNA fragmentation in leukemia lines and in mononuclear cells from a Ph + acute lymphoblastic leukemia (ALL) patient. "
07/01/2014 - "In conclusion, salinosporamide A displayed potent antileukemic activity against bortezomib-resistant leukemia cells. "
10/15/2011 - "We aim to understand the relationship between the irreversible inhibition of the proteasome and induction of cell death in leukemia cells by using analogs of marizomib that display reversible and irreversible properties. "
04/30/2009 - "Overall, our results suggest that crosstalk by NPI-0052 and HDACi are contributing, along with caspase-8 activation and oxidative stress, to their synergistic cytotoxic effects in leukemia cells, reinforcing the potential clinical utility of combining these 2 agents."